Momenta Pharmaceuticals, Inc.  

(Public, NASDAQ:MNTA)   Watch this stock  
Find more results for Momenta, Inc
21.27
-1.16 (-5.17%)
Jul 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 20.41 - 21.60
52 week 9.38 - 25.56
Open 21.58
Vol / Avg. 1.71M/1.09M
Mkt cap 1.40B
P/E     -
Div/yield     -
EPS -1.78
Shares 65.80M
Beta 2.35
Inst. own 80%
Jul 29, 2015
Q2 2015 Momenta Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 11, 2015
Momenta Pharmaceuticals Inc Annual Shareholders Meeting (Estimated)
Jun 9, 2015
Momenta Pharmaceuticals Inc Annual Shareholders Meeting
May 19, 2015
Momenta Pharmaceuticals Inc at UBS Global Healthcare Conference
May 13, 2015
Momenta Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 7, 2015
Momenta Pharmaceuticals Inc at Deutsche Bank Health Care Conference
May 1, 2015
Q1 2015 Momenta Pharmaceuticals Inc Earnings Call
May 1, 2015
Q1 2015 Momenta Pharmaceuticals Inc Earnings Release
Apr 16, 2015
Momenta Pharmaceuticals Inc Announces FDA Approval of ANDA for GlatopaT Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -255.51% -188.71%
Operating margin -257.85% -190.23%
EBITD margin - -173.58%
Return on average assets -34.01% -34.41%
Return on average equity -41.48% -41.41%
Employees 256 -
CDP Score - -

Address

675 W Kendall St
CAMBRIDGE, MA 02142-1110
United States - Map
+1-617-4919700 (Phone)
+1-617-6210431 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Momenta Pharmaceuticals, Inc. (Momenta) is a biotechnology company focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has three product areas: Complex Generics, Biosimilars and Novel Therapeutics. The Company’s product, a generic version of Lovenox (enoxaparin sodium injection), was approved by the United States Food and Drug Administration. The Company is developing Complex Generics, such as Enoxaparin Sodium Injection and M356. The Company is developing Bosimilars, including M923 and M834. The Company is developing Novel Therapeutics, including Necuparanib. The Company is developing M356 as a generic version of Copaxone. The Company is developing M923, a biosimilar of HUMIRA. The Company is developing M834 as a biosimilar of ORENCIA.

Officers and directors

James R. Sulat Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Craig A. Wheeler President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard P. Shea Chief Financial Officer, Senior Vice President
Age: 63
Bio & Compensation  - Reuters
Michael Franken M.D. President - Biosimilars Business, Senior Vice President
Age: 50
Bio & Compensation  - Reuters
Ganesh Venkataraman Kaundinya Ph.D. Senior Vice President - Research, Chief Scientific Officer
Age: 48
Bio & Compensation  - Reuters
Bruce A. Leicher Senior Vice President, General Counsel, Secretary
Age: 59
Bio & Compensation  - Reuters
John E. Bishop Ph.D. Senior Vice President - Pharmaceutical Sciences
Age: 53
Bio & Compensation  - Reuters
James M. Roach M.D. Senior Vice President - Development, Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
John K. Clarke Independent Director
Age: 61
Bio & Compensation  - Reuters
Bruce L. Downey Independent Director
Age: 68
Bio & Compensation  - Reuters